Rupa Sunil Shah, a Person Acting in Concert (PAC 5), acquired 53,520 shares of Parmax Pharma off-market. This transaction increases the PAC group's total shareholding to 20.54%.

Parmax Pharma: Rupa Shah (PAC 5) Acquires Shares Off-Market

53,520 shares acquired by Rupa Sunil Shah (PAC 5) at Rs 35 each.
Consolidated shareholding of Acquirer + PACs rises to 20.54%.

Reader Takeaway: Promoter group stake increase; regulatory compliance filing.

What just happened

Rupa Sunil Shah, identified as a Person Acting in Concert (PAC 5), has completed an off-market acquisition of 53,520 shares in Parmax Pharma Limited on June 16, 2026. Each share was purchased at Rs 35.00.

Why this matters

This transaction increases the total consolidated shareholding of the Acquirer and Persons Acting in Concert (PACs) from 19.11% to 20.54%. This filing ensures transparency regarding shareholding changes during an offer period.

The backstory

Parmax Pharma Ltd is a pharmaceutical company. Shareholding changes within promoter groups and their associated persons are common during various corporate actions and are subject to SEBI regulations.

What changes now

The shareholding pattern of Parmax Pharma will reflect this increased stake by the PAC group. This is a procedural update following the acquisition.

Risks to watch

As this is an off-market transaction within a PAC group, direct market impact is limited. However, any significant change in promoter holding could be a factor for investors to monitor.

Peer comparison

(No peer comparison data available from the filing.)

Context metrics (time-bound)

• Date of Acquisition: June 16, 2026
• Shares Acquired: 53,520
• Purchase Price: Rs 35.00 per share
• Pre-Acquisition Total Shareholding (Acquirer + PACs): 19.11%
• Post-Acquisition Total Shareholding (Acquirer + PACs): 20.54%

What to track next

Investors should continue to monitor subsequent regulatory filings for any further changes in shareholding or developments related to the offer period.